|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Pain Therapeutics for the New Millennium | ||||||||||||||||
| February 28, 2001 | ||||||||||||||||
|
SMi, The Hatton Conference Centre, London 4th - 5th June 2001 The ultimate pain therapeutics event you cannot afford to miss..…. SMi’s 2nd Annual Event PAIN THERAPEUTICS FOR THE NEW MILLENNIUM 4th & 5th June 2001, The Hatton, London A unique opportunity to learn from leading industry experts including: Dr Ray Hill, Executive Director, Pharmacology, Merck Sharp and Dohme Dr Robert Allen, Vice President Global R&D, AstraZeneca Dr James Sullivan, Divisional Vice President, Neurological & Urological Diseases Research, Abbott Dr Mark Versavel, Director, Global R&D, CNS, Parke-Davis/Pfizer Global Research R&D Dr Chas Bountra, Head, Pain Research, GlaxoSmithKline Dr Henning Draheim, Project Team Leader, Boehringer Ingelheim Laszlo Urban, Deputy Unit Head, NIMS, Novartis Dr Fabio Bordi, Senior Scientist, Biology Department, GlaxoSmithKline Dr Sharon Bingham, Investigator, GlaxoSmithKline Dr Geoffrey Guy, Chairman, GW Pharmaceuticals Dr Piero Del Soldato, Executive Vice President Science & Technology, NicOx Dr William Sietsema, Senior Director, Clinical Research, Skeletal Disease & Inflammation, Kendle International Dr Steven Quay, Chairman, President & Chief Executive Officer, Nastech Dr Garth Whiteside, Senior Research Scientist, SynGenix Dr Paul Wotton, Vice President Corporate Development, Eurand Pharmaceuticals Jamal Temsamani, Director, Preclinical R&D, Synt:em Dr Jack Kessler, Chairman & Chief Executive Officer, Symbollon Dr Peter Evans, Consultant Anaesthetist & Director, Pain Management Service, Hammersmith Hospitals NHS Trust Dr Anita Holdcroft, Reader in Anaesthesia, Imperial College School of Medicine Chaired by: Prof Praveen Anand, Professor, Clinical Neurology & Head, Peripheral Neuropathy Unit, Imperial College School of Medicine Dr Randall Carpenter, Vice President, Clinical R&D, Adolor Day One – 4th June 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Prof Praveen Anand, Professor, Clinical Neurology & Head, Peripheral Neuropathy Unit, Imperial College School of Medicine STRATEGIC OVERVIEW OF THE GLOBAL PAIN DRUG MARKET 9.10 Emerging technologies and development issues Structure of the world-wide analgesia market Current pain drugs, therapeutic modalities, and pipeline analysis Identifying the deficiencies in current pain management New drug targets for pain relief Trial design pitfalls and reducing measurement bias Dr William Sietsema, Senior Director, Clinical Research, Skeletal Disease & Inflammation, Kendle International FROM GENES TO PAIN THERAPEUTICS 9.40 The challenges in turning a molecular target into a marketable drug The basic mechanisms of pain and how this information can be used to devise rational pain medicines Identification of targets: too many targets too little time? Target identification vs target validation Value and limitation of animals: don’t forget the patient!! From target to patentable ligand-reverse pharmacology Diagnostics and molecular medicine – the way forward? Laszlo Urban, Deputy Unit Head, NIMS, Novartis CHALLENGES IN THE DEVELOPMENT OF THERAPIES FOR NEUROPATHIC PAIN 10.20 Academic and industry perspectives Heterogeneity of a syndrome: global hurdles Animal models: lessons from our furry friends A mechanistic based approach: clinical perspectives Clinically meaningful relief: room for improvement Regulatory issues: in search of harmony Expanding opportunities: the future is now Dr Robert Allen, Vice President Global R&D, AstraZeneca 11.00 Morning Coffee TREATMENT OF NEUROPATHIC PAIN WITH GABAPENTIN 11.20 Anti-epileptic drug is effective in neuropathic pain From anti-epileptic drug to neuropathic pain treatment Effects in neuropathic pain models Pharmacokinetics Multiple-centre, controlled clinical studies: results Adverse events and tolerability Dr Mark Versavel, Director, Global R&D CNS, Parke-Davis/Pfizer Global Research R&D NO-RELEASING ANALGESICS: NOVEL CLASSES OF VERY EFFECTIVE AND SAFE COMPOUNDS 12.00 Safety and efficacy profile of NO-releasing analgesics New classes of NO-releasing analgesics has recently been described which exert remarkable pharmacological activities but produce significantly less gastrointestinal and renal toxicity than native drugs The rationale of the project is based upon the multiple pharmacological and cytoprotective activities of NO, that is released in a limited and controlled way via an enzymatic mechanism The pharmacological profile of NCX 4016 and NCX 701 In conclusion, NO-releasing drugs have better efficacy and safety that the native agents and warrant further investigations in animals and humans Dr Piero Del Soldato, Executive Vice President Science & Technology, NicOx 12.40 Networking Lunch NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS (NNRS) 2.00 A novel target for the development of broad spectrum analgesic agents Rationale for NNRs as a molecular target for pain Epibatidine, a non-opioid, non-NSAID analgesic agent - strengths and limitations Preclinical pharmacology of ABT-594 Towards a mechanistic understanding of the analgesic effects of NNR compounds across different pain states Potential impact of ABT-594 on pain management Dr James Sullivan, Divisional Vice President, Neurological & Urological Diseases Research, Abbott NEURONAL PLASTICITY AND THE ESTABLISHMENT OF CHRONIC PAIN STATES 2.40 Adenosine receptor agonists, sodium channel inhibitors and INOS inhibitors Heterogeneity of chronic somatic and visceral pain Underlying pathological mechanisms Role of sodium channels, adenosine receptors and inducible nitric oxide synthase Challenges in drug discovery Dr Chas Bountra, Head, Pain Research, GlaxoSmithKline 3.20 Afternoon Tea NERVE TARGETED PHARMACEUTICALS AND NEUROPATHIC PAIN 3.40 Axonal transport of compounds is effective in treating neuropathic pain Axonal transport of compounds versus systemic delivery; anatomical and chemical targeting Tracer studies following injection into peripheral tissue Tripartite molecules for amplification Axonally delivered Gabapentin is effective in animal models of neuropathic pain Further potential of axonal transport; brain delivery, peptides, proteins and nucleic acid Dr Garth Whiteside, Senior Research Scientist, SynGenix EXCITATORY AMINO ACID RECEPTORS AND CHRONIC PAIN 4.20 Case study: the NMDA antagonist GV-196771 The role of NMDA receptors in chronic pain states Intervening the NMDA pathway GV-196771: anti-hyperalgesic and anti-allodynic profile Side effects profile and reduction of morphine-induced tolerance Dr Fabio Bordi, Senior Scientist, Biology Department, GlaxoSmithKline 5.00 Chairman’s Closing Remarks and Close of Day One 5.10 DRINKS RECEPTION Day Two – 5th June 8.30 Re-registration and Coffee 9.00 Chairman's Opening Remarks Dr Randall Carpenter, Vice President, Clinical R&D, Adolor MEETING THE NEEDS OF PATIENTS 9.10 The limitations of conventional therapy The relationship between, distress, pain and disability Managing pain problems over time The impact of medical therapies Beliefs and values of drugs as judged by the patient Integrating treatments into a pattern of care Why do the pills fail? Dr Peter Evans, Consultant Anaesthetist & Director, Pain Management Service, Hammersmith Hospitals NHS Trust ANIMAL MODELS: TRANSGENIC MICE FOR PAIN RESEARCH 9.40 Good models for painful clinical conditions? Elucidating gene function in an intact organism: relevance and implications for drug discovery and development Advantages of this approach Target validation Provision of disease models Functional analysis of novel genes Recent methodologies Inducible and conditional knockouts Limitation of transgenics in pain research Dr Ray Hill, Executive Director, Pharmacology, Merck Sharp and Dohme A NEW TREATMENT FOR BREAST PAIN 10.20 Moderate and severe cyclic mastaglia can now be safely treated 1 in 5 women suffer from clinical mastaglia Hormonally based therapies are inappropriate Homeopathic treatments are inadequate Novel in situ active drug delivery Published clinical studies support efficacy Symbollon’s clinical trial results confirm literature Dr Jack Kessler, Chairman & Chief Executive Officer, Symbollon 11.00 Morning Coffee MODELS OF NOCICEPTION IN TRANSGENIC MICE 11.20 Interpretation and lessons to be learnt What can transgenic mice tell us about nociceptive processing? Models and methodology used Early vs late stage testing Importance of mouse strain Interpretation of data based on these points Dr Sharon Bingham, Investigator, GlaxoSmithKline CANNABINOIDS AND PAIN 12.00 Development of cannabinoids as analgesics Pain therapies in the past Endogenous cannabinoids Pharmaceutical targets Limitations of cannabinoid therapies Clinical trials Dr Anita Holdcroft, Reader in Anaesthesia, Imperial College School of Medicine 12.40 Networking Lunch CANNABIS BASED MEDICINES 1.40 Therapeutic role in neurogenic pain Selected cannabis strains yield defined cannabinoid ratios Drug delivery technology optimises rate and extent of absorption Patient titration is key Clinical indication and pain management with cannabinoids Dr Geoffrey Guy, Chairman, GW Pharmaceuticals ACETYLCHOLINE RECEPTORS AND ACID SENSING ION CHANNELS 2.20 Ion channels as targets in chronic pain research Voltage-gated channels I: TTX sensitive and resistant Na+ channels Voltage-gated channels II: the Cav2 family of Ca2+ channels Ligand-gated ion channels I: NMDA and non-NMDA Glutamate receptors Ligand-gated ion channels II: vanilloid receptors, ASIC channels Dr Henning Draheim, Project Team Leader, Boehringer Ingelheim DELIVERING PERFORMANCE ENHANCED ANALGESICS 3.00 The role of drug delivery systems in designing patient friendly medicines Market and clinical needs for optimised pain therapeutics Why drug delivery matters for patients and pharmaceutical companies The use of drug delivery technology to develop better pain products Examples of performance enhanced approaches to pain medication The drug delivery company’s role in pain management product development Dr Paul Wotton, Vice President Corporate Development, Eurand 3.40 Afternoon Tea PEP:TRANS: A NEW APPROACH TO BRAIN DELIVERY 4.00 Case study: Synt:em The BBB and drug delivery to the CNS: a brief overview Pep:trans: mechanism of action An effective solution for delivery of analgesics Other potential applications Jamal Temsamani, Director, Preclinical R&D, Synt:em INTRANASAL DELIVERY FOR BREAKTHROUGH PAIN 4.30 Update on Nastech's pain management franchise Positioned to fulfil the unmet medical need for the treatment of breakthrough pain Intranasal administration provides for direct absorption into the systemic circulation, by-passing problems that occur with oral administration Blood plasma concentrations resemble those seen with injectable dosage forms Rapid onset of action and painless therapy Dr Steven Quay, Chairman, President & Chief Executive Officer, Nastech 5.00 Chairman's Closing Remarks and Close of Conference PAIN THERAPEUTICS FOR THE NEW MILLENNIUM 4th & 5th June 2001, The Hatton, London Dear Pharmaceutical Executive, The new therapeutic agents emerging for the treatment of acute and chronic pain are revolutionising the treatment of pain sufferers across the globe. Not only has there been an explosion in the number of drugs available within this field, even better, these novel analgesics promise minimal side effects. With this knowledge in mind, our challenge at SMi was to assemble key industry peers involved in analgesic research that would provide pertinent and up-to-date information on the key innovations within this exciting research field. As you can see from this brochure we have more than achieved our goal. Why should you attend this event? This is your unique opportunity to meet senior industry executives and seek their advice and opinions. This, our 2nd Pain Drugs event, promises to be as successful as the first and will highlight key issues including the challenges associated with the development of neuropathic therapies, aminal models in pain research, NO-releasing analgesics, novel drug delivery options, regulatory issues and the use of cannabinoids in pain relief. With highly acclaimed industry leaders delivering these timely presentations this is indeed an excellent opportunity for lively discussion on the new paths emerging within pain research. To attend this essential forum please register now using the booking form on the back of the brochure or visit www.smi-online.co.uk/pain.asp to register online. I look forward to seeing you in London in June. Yours faithfully, Susie Palmer Ph.D. Conference Producer Tel: +44 (0)20 7827 6042 Email: spalmer@smi-online.co.uk |
||||||||||||||||
| Organized by: | Dr Susie Palmer | |||||||||||||||
| Invited Speakers: | Dr Ray Hill, Executive Director, Pharmacology, Merck Sharp and Dohme Dr Robert Allen, Vice President Global R&D, AstraZeneca Dr James Sullivan, Divisional Vice President, Neurological & Urological Diseases Research, Abbott Dr Mark Versavel, Director, Global R&D, CNS, Parke-Davis/Pfizer Global Research R&D Dr Chas Bountra, Head, Pain Research, GlaxoSmithKline Dr Henning Draheim, Project Team Leader, Boehringer Ingelheim Laszlo Urban, Deputy Unit Head, NIMS, Novartis Dr Fabio Bordi, Senior Scientist, Biology Department, GlaxoSmithKline Dr Sharon Bingham, Investigator, GlaxoSmithKline Dr Geoffrey Guy, Chairman, GW Pharmaceuticals Dr Piero Del Soldato, Executive Vice President Science & Technology, NicOx Dr William Sietsema, Senior Director, Clinical Research, Skeletal Disease & Inflammation, Kendle International Dr Steven Quay, Chairman, President & Chief Executive Officer, Nastech Dr Garth Whiteside, Senior Research Scientist, SynGenix Dr Paul Wotton, Vice President Corporate Development, Eurand Pharmaceuticals Jamal Temsamani, Director, Preclinical R&D, Synt:em Dr Jack Kessler, Chairman & Chief Executive Officer, Symbollon Dr Peter Evans, Consultant Anaesthetist & Director, Pain Management Service, Hammersmith Hospitals NHS Trust Dr Anita Holdcroft, Reader in Anaesthesia, Imperial College School of Medicine |
|||||||||||||||
| Deadline for Abstracts: | all speaker slots now taken | |||||||||||||||
| Registration: | Register online at www.smi-online.co.uk/pain.asp Call Customer Services on +44(0) 20 7252 2222 or email customer_services@smi-online.co.uk |
|||||||||||||||
| E-mail: | customer_services@smi-online.co.uk | |||||||||||||||
| Posted by: | Dr Susie Palmer | |||||||||||||||
| Host: | 213.38.112.46 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||